重组人血管内皮抑制素(恩度)联合放疗同步治疗中晚期宫颈癌48例的近期疗效

The efficacy of Endostar combined with radiotherapy for advanced cervical cancer

目的:观察重组人血管内皮抑制素(恩度)同步放疗对中晚期宫颈癌的近期疗效。方法:将48例中晚期(Ⅱb-Ⅳa期)宫颈癌患者随机分为两组:单纯放疗组(RT组)24例,恩度联合放疗组(RT+E组)24例。两组放疗方法相同。RT+E组在放疗开始每天一次恩度7.5mg/m2 iv drop,共4周。结果:近期临床疗效:RT+E组CR 18例(75.0%),PR 5例(20.8%),NC 1例(4.2%),有效率(CR+PR)95.8%;RT组CR 8例(33.3%),PR 10例(41.7%),NC 6例(25.0%),有效率(CR+PR)75.0%,RT+E组的CR及有效率均高于RT组,差异有显著性。结论:重组人血管内皮抑制素(恩度)同步放疗可提高中晚期宫颈癌的近期疗效,毒性反应没有增加。

Objective：To investigate the outcome of Endostar combined with radiotherapy for advanced cervical cancer. Methods： Forty-eight cases with cervical cancer （FIGO Ⅱb to Ⅳa）were divided randomly into two groups,radiotherapy alone （RT group） and Endostar combined with radiotherapy group （RT＋E group）.There was no difference of radiotherapy between the two groups,The RT＋E cases who accepted 7.5mg/m2 Endostar during the radiation.These regimen were given for 4 weeks.Results：The complete remission rate was 75.0%and partial remission rate was 20.8%in RT＋E,the complete remission rate was 33.3%and partial remission rate was 41.7%in RT.The total response rate and complete remission rate of RT＋E group was higher than that of RT group.There was significant difference between the two groups.Conclusion：Endostar combined with radiotherapy can improve the outcome of advanced cervical cancer,and the adverse effects was not raised.